ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1436

Incidence Rate, Predictors and Outcome of Stroke in Patients with ANCA Associated Vasculitis – A Population-based Study

Dennis Tabakovic1, Rona Smith2, David Jayne3 and Aladdin Mohammad4, 1Lund University, Lund, Skane Lan, Sweden, 2University of Cambridge, Cambridge, United Kingdom, 3Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Cambridge, United Kingdom, 4Lund University, Lund, Sweden. Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Lund, Sweden

Meeting: ACR Convergence 2020

Keywords: Epidemiology, Mortality, neurology, prognostic factors, risk factors

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2020

Title: Vasculitis – ANCA-Associated Poster

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: To study the incidence rate, predictors and outcome of stroke in patients with ANCA-associated vasculitis (AAV) within a defined population in southern Sweden.

Methods: The study included a total of 325 patients diagnosed with AAV within a defined geographical area in Sweden (1997-2016). The diagnosis and classification of AAV was confirmed by case record review using the European Medicines Agency (EMA) algorithm. To identify AAV cases with stroke, two sources were used: (i) The Swedish Stroke Register (Riksstroke): a national stroke register operated since 1994 which includes all cases of stroke diagnosed at stroke-units in Sweden , (ii) The Skåne healthcare register (SHR), an administrative local register of all healthcare services provided to the population in Skåne, was used to identify patients diagnosed at departments not specialized in stroke-care. Diagnosis of stroke for cases identified by the SHR were verified by case record review. From the Riksstroke register we identified 10 controls for each AAV-patient, matched for age, sex and years of stroke diagnosis. Incidence rate of stroke in AAV-patients was calculated per 1000 person-years of follow-up. The person-year was calculated from date of AAV-diagnosis to either date of stroke, death or end of study, December 2018. Using data from the Swedish background population, standardized incidence ratio (SIR) of stroke was estimated. Cox-regression analysis was utilized to investigate predictors of stroke in AAV.

Results: Out of 325 AAV-patients, 20 (6%) suffered a stroke during the follow-up period. The incidence rate of stroke in AAV was 9.7 per 1000 person-years (95% CI 5.5-14.0) and was highest within the first year after AAV-diagnosis, 20.5 per 1000 person-years of follow-up (95% CI 4.1-36.9). Patients diagnosed with AAV at age < 65 years had 3.2-fold increased risk of stroke compared with background population (Table 1). Platelet count at AAV diagnosis was identified as an independent predictor of stroke (Table 2). There were no differences in survival rates or other outcome measures of stroke between AAV patients and their controls. While comparing AAV patients with and without stroke, a higher survival rate in PR3-positive patients compared to MPO-positive patients was observed (Figure 1).

Conclusion: Incidence rate of stroke in AAV is highest during first year after AAV diagnosis and significantly higher than that of the background population among patients younger than 65 years at AAV diagnosis. An elevated platelet count at AAV-diagnosis was able to predict an increased risk of stroke. Prophylactic treatment with antithrombotic and anticoagulant drugs to prevent stroke-occurrence requires further exploration.


Disclosure: D. Tabakovic, None; R. Smith, None; D. Jayne, Chemocentryx, 1, 2, 5, GlaxoSmithKline, 1, 2, 5, AstraZeneca, 1, 2, 5, Aurinia, 1, 2, 5, Bristol-Myers Squibb Company, 1, 2, 5, Boehringer Ingelheim, 1, 2, 5; A. Mohammad, None.

To cite this abstract in AMA style:

Tabakovic D, Smith R, Jayne D, Mohammad A. Incidence Rate, Predictors and Outcome of Stroke in Patients with ANCA Associated Vasculitis – A Population-based Study [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/incidence-rate-predictors-and-outcome-of-stroke-in-patients-with-anca-associated-vasculitis-a-population-based-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/incidence-rate-predictors-and-outcome-of-stroke-in-patients-with-anca-associated-vasculitis-a-population-based-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology